Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular P… (NCT06886009) | Clinical Trial Compass
WithdrawnNot Applicable
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
Stopped: Sponsor decision
South Korea0Started 2026-03-31
Plain-language summary
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
Who can participate
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Patients starting Spesolimab IV for the first time in accordance with the approved label in Korea (complete enumeration for the first 2 years after product launch)
* Patients with generalized pustular psoriasis (GPP) flare
* Age \>/=19 years at enrolment
* Patients who have signed the data release consent form
Exclusion criteria:
* Patients with Severe or life-threatening hypersensitivity to Spesolimab or to any of the excipients
* Patients with clinically important active infections (e.g. active tuberculosis)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Incidence of adverse events (AEs)
Timeframe: Up to 24 weeks
2
Incidence of adverse drug reactions (ADRs)
Timeframe: Up to 24 weeks
3
Incidence of serious adverse events (SAEs)
Timeframe: Up to 24 weeks
4
Incidence of serious adverse drug reactions (SADRs)
Timeframe: Up to 24 weeks
5
Incidence of unexpected adverse drug reactions
Timeframe: Up to 24 weeks
6
Incidence of adverse events of special interest (AESIs)
Timeframe: Up to 24 weeks
7
Incidence of adverse events leading to temporary or permanent discontinuation